勘误：使用聚（ADP-核糖）聚合酶抑制剂后发生的骨髓增生异常综合征/急性髓系白血病：上市后监测数据的真实世界分析。
Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data.
作者信息
Zhao Quanfeng, Ma Pan, Fu Peishu, Wang Jiayu, Wang Kejing, Chen Lin, Yang Yang
机构信息
Department of Pharmacy, The First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China.
Department of Pharmacy, Women and Children's Hospital of Chongqing Medical University, Chongqing, China.
出版信息
Front Pharmacol. 2022 Aug 11;13:990048. doi: 10.3389/fphar.2022.990048. eCollection 2022.
Abstract
[This corrects the article DOI: 10.3389/fphar.2022.912256.].
摘要
[本文更正了文章DOI：10.3389/fphar.2022.912256。]
相似文献
1
Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data.勘误：使用聚（ADP-核糖）聚合酶抑制剂后发生的骨髓增生异常综合征/急性髓系白血病：上市后监测数据的真实世界分析。
Front Pharmacol. 2022 Aug 11;13:990048. doi: 10.3389/fphar.2022.990048. eCollection 2022.
2
Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.使用聚腺苷二磷酸核糖聚合酶（PARP）抑制剂后发生的骨髓增生异常综合征/急性髓系白血病：上市后监测数据的真实世界分析
Front Pharmacol. 2022 Jun 15;13:912256. doi: 10.3389/fphar.2022.912256. eCollection 2022.
3
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.接受 PARP 抑制剂治疗的患者的骨髓增生异常综合征和急性髓系白血病：随机对照试验的安全性荟萃分析和世界卫生组织药物警戒数据库的回顾性研究。
Lancet Haematol. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18.
4
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.聚 ADP - 核糖聚合酶（PARP）抑制剂可诱导髓系白血病细胞凋亡：对髓系白血病和骨髓增生异常综合征的治疗潜力。
Haematologica. 2009 May;94(5):638-46. doi: 10.3324/haematol.2008.001933.
5
Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.聚（ADP - 核糖）聚合酶抑制剂相关的骨髓增生异常综合征/急性髓系白血病：FAERS数据库的药物警戒分析
ESMO Open. 2021 Feb;6(1):100033. doi: 10.1016/j.esmoop.2020.100033. Epub 2021 Jan 11.
6
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.DNA 修复基因 CtIP 和 MRE11 中的微卫星不稳定性诱导突变导致髓系恶性肿瘤对聚（ADP-核糖）聚合酶抑制剂敏感。
Haematologica. 2013 Sep;98(9):1397-406. doi: 10.3324/haematol.2012.079251. Epub 2013 Jan 24.
7
PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia.PARP抑制剂——了解骨髓增生异常综合征和急性髓系白血病的风险
Lancet Haematol. 2021 Feb;8(2):e97-e99. doi: 10.1016/S2352-3026(20)30375-6. Epub 2020 Dec 18.
8
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.抑制聚（ADP-核糖）聚合酶1通过抑制骨髓增殖性白血病病毒癌基因来预防急性髓系白血病。
Oncotarget. 2015 Sep 29;6(29):27490-504. doi: 10.18632/oncotarget.4748.
9
Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.接受聚ADP核糖聚合酶抑制剂治疗的卵巢癌女性患者的继发性血液系统恶性肿瘤
Eur J Cancer. 2021 Nov;157:59-62. doi: 10.1016/j.ejca.2021.08.016. Epub 2021 Sep 3.
10
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.聚ADP - 核糖聚合酶（PARP）抑制剂可诱导髓系白血病细胞凋亡：对髓系白血病和骨髓增生异常综合征的治疗潜力。
Haematologica. 2021 Aug 1;106(8):2294. doi: 10.3324/haematol.2020.262857.
引用本文的文献
1
Haematologic outcomes and associated clinical characteristics among patients receiving Olaparib therapy in the UAE: a retrospective chart review.阿联酋接受奥拉帕尼治疗患者的血液学结果及相关临床特征：一项回顾性图表审查
Ann Med. 2025 Dec;57(1):2440631. doi: 10.1080/07853890.2024.2440631. Epub 2024 Dec 13.
Zotero 插件